New Blood Test Shows Promise in Identifying Who Will Develop Type 1 Diabetes

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. By the time symptoms appear, much of that damage is already done. Researchers have long sought biomarkers—detectable signs in blood or other tissues—that could predict who will develop the disease months or years before diagnosis.

Autoantibodies (proteins the immune system makes against the body's own proteins) are one known early marker, but they don't tell the whole story. Not everyone with autoantibodies develops type 1 diabetes, and there's likely much more happening in the body before symptoms arrive.

Extracellular vesicles (EVs) are tiny particles that cells release into the bloodstream. They carry proteins and other cargo that reflect what's happening inside those cells. Because they carry signatures from their cell of origin, EVs in blood plasma are like messengers that reveal what different tissues are doing—including whether the immune system is attacking.

By analyzing the proteins packed inside these vesicles, researchers hoped to find a more complete picture of the biological changes that precede type 1 diabetes.

The research team captured extracellular vesicles from blood samples of 19 people with circulating autoantibodies against islet proteins (indicating early autoimmunity) and 17 healthy control individuals. Using advanced mass spectrometry technology, they identified and measured over 5,400 different proteins—far more than previous studies could detect.

The comparison revealed 448 proteins that were present in different amounts between the two groups. Notably, 69 of these differentially abundant proteins had previously been confirmed as authentic EV proteins, strengthening confidence in the findings.

The researchers then tested whether these proteins could predict who had autoimmunity using a machine learning approach. The model achieved an 81% accuracy rate—meaning it correctly identified people with early autoimmune signs about four out of five times.

When researchers analyzed which biological pathways were overrepresented among the differentially abundant proteins, a picture emerged: the data pointed to immune system dysfunction as expected, but also to problems with lipid (fat) metabolism. This finding suggests that type 1 diabetes involves more than just autoimmune attack—metabolic changes may also play a role in disease development.

These insights could eventually help researchers understand not just who is at risk, but how and why the disease develops.

This study demonstrates that extracellular vesicle proteins hold promise as early detection biomarkers. The 81% accuracy is encouraging but not yet ready for clinical use. Larger studies are needed to confirm these findings, test the approach in different populations, and determine whether this protein signature remains stable over time.

If validated, such a blood test could someday help identify people at highest risk of developing type 1 diabetes, opening the door to early interventions. For now, this work represents one more step toward understanding the earliest biological changes that signal the onset of disease.

Source: Proteomics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.